Key statistics dashboard for Entrada Therapeutics, Inc. (TRDA). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches.
Stock Data
| Price | $6.89 |
| Market Cap | $267M |
| Enterprise Value | $216.7M |
| Beta | -0.15 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.74 |
| Price / Book | 1.25 |
| P/S | 57.08 |
| EV/EBITDA | -1.31 |
| EV/Sales | 46.25 |
| EV/FCF | -1.61 |
| P/FCF | -1.99 |
| Earnings Yield | -56.99% |
| FCF Yield | -50.23% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -754.72% |
| EBIT Margin | -3520.25% |
| EBITDA Margin | -3518.31% |
| Operating Margin | -3767.07% |
| Net Margin | -3537.73% |
| Return on Equity | -57.61% |
| Return on Assets | -55.47% |
| Return on Invested Capital | -62.61% |
| Return on Capital Employed | -63.61% |
Financial Health
| Current Ratio | 10.89 |
| Quick Ratio | 10.89 |
| Cash Ratio | 4.65 |
| Debt / Equity | 0.21 |
| Debt / Assets | 16.24% |
| Net Debt / EBITDA | 0.31 |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 2.17 |
Per-Share Data
| Revenue per share | 0.11 |
| Book Value per share | 5.53 |
| Cash per share | 5.28 |
| FCF per share | -3.18 |
| Tangible Book Value per share | 5.53 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 6 |
| Avg rating (1-5) | 0.67 |
Related companies: ACHV · ALLO · ARCT · AVIR · CAPR · HUMA · IMRX
Explore sector: Healthcare · Biotechnology
More sections of TRDA: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks